Anticoagulation for Stroke Prevention in Atrial Fibrillation and Treatment of Venous Thromboembolism and Portal Vein Thrombosis in Cirrhosis
Publication Date: May 30, 2024
Last Updated: June 10, 2024
Atrial Fibrillation in Patients with Liver Disease
We recommend that patients with Child-Pugh A or B cirrhosis with AF and CHA2DS2VASc score of 2 or greater in males and 3 or greater in females be anticoagulated for stroke prevention as per current guideline recommendations in patients without cirrhosis unless otherwise contraindicated. There is inadequate evidence with respect to the benefit and risk of anticoagulation in patients with Child-Pugh C cirrhosis.
6731
We suggest that patients with Child-Pugh A or B cirrhosis with AF and CHA2DS2VASc score of 1 in males and 2 in females be anticoagulated for stroke prevention as per current guideline recommendations in patients without cirrhosis unless otherwise contraindicated. There is inadequate evidence with respect to the benefit and risk of anticoagulation in patients with Child-Pugh C cirrhosis.
6731
We suggest that DOACs at standard doses are used in patients with AF and Child-Pugh A or B cirrhosis in preference to VKAs based on available evidence suggesting greater efficacy and safety with DOACs as compared to VKAs.
6731
There is inadequate in-vivo pharmacokinetic or clinical evidence to recommend for or against specific DOACs for stroke prevention in AF in cirrhosis.
6731
We suggest a case-by-case consideration of LAAO in select patients with AF and cirrhosis at high risk of stroke who are not candidates for, or who have failed, anticoagulation and who are expected to have a reasonable life expectancy (i.e. patient awaiting transplant).
6731
Deep Vein Thrombosis/Pulmonary Embolism in Patients with Liver Disease
We recommend patients with cirrhosis and acute DVT/PE are offered treatment with anticoagulation barring a contraindication such as active bleeding, in keeping with current guideline recommendations for patients without cirrhosis.
6731
We suggest the use of either DOAC or LMWH +/- VKA for patients with Child-Pugh A or B cirrhosis based on patient preference.
6731
We suggest LMWH alone (or as a bridge to VKA in patients with a normal baseline INR) in patients with Child-Pugh C cirrhosis.
6731
We suggest anticoagulation should not be withheld in patients with moderate thrombocytopenia secondary to advanced liver disease. A case-by-case decision should be made when the platelet count is <50 x 109 /L, based on site and extent of thrombosis, risk of thrombus extension, patient preference and presence of active bleeding/additional bleeding risk factors.
6731
Portal Vein Thrombosis in Patients with Cirrhosis
We recommend anticoagulation for all patients with cirrhosis with symptomatic PVT for a minimum of six months.
6731
We suggest anticoagulation for all patients with cirrhosis with asymptomatic, but progressing PVT for a minimum of six months, unless there are clear contraindications to anticoagulation.
6731
We recommend continuing extended anticoagulation for all patients with cirrhosis and PVT who are candidates for liver transplantation unless patients are actively bleeding.
6731
Anticoagulation may be considered in patients with cirrhosis and asymptomatic PVT who are not candidates for liver transplantation on a case-by-case basis as anticoagulation may be associated with a survival benefit. If anticoagulation is initiated, we recommend regular reassessment of bleeding risk (for example at six monthly intervals) and withdrawal of anticoagulation in the event of active bleeding or with significant increase in bleeding risk.
6731
We recommend evaluating for the presence of varices and ensuring adequate management prior to initiation of anticoagulant therapy and refer to other guidance documents for recommended strategies.
6731
We suggest the use of either DOAC or LMWH +/- VKA for patients with Child-Pugh A or B cirrhosis.
6731
We suggest LMWH alone (or as a bridge to VKA in patients with a normal baseline INR) in patients with Child-Pugh C cirrhosis.
6731
The information in this patient summary should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.
Title
Anticoagulation for Stroke Prevention in Atrial Fibrillation and Treatment of Venous Thromboembolism and Portal Vein Thrombosis in Cirrhosis
Authoring Organization
International Society on Thrombosis and Haemostasis
Publication Month/Year
May 30, 2024
Last Updated Month/Year
June 24, 2024
Country of Publication
Global
Document Objectives
Whilst advanced liver disease was previously considered to be an acquired bleeding disorder, there is increasing recognition of an associated prothrombotic state with patients being at higher risk of atrial fibrillation (AF) and stroke and venous thromboembolism including portal vein thrombosis (PVT). We review the available literature on epidemiology, pathophysiology and risk factors and provide guidance on anticoagulant management of these conditions in adults with cirrhosis. In patients with Child-Pugh A or B cirrhosis and AF, we recommend anticoagulation with standard dose direct oral anticoagulants (DOACs) in accordance with cardiology guideline recommendations for patients without liver disease. In those with Child-Pugh C cirrhosis, there is inadequate evidence with respect to the benefit and risk of anticoagulation for AF. For patients with cirrhosis and acute deep vein thrombosis or pulmonary embolism, we recommend anticoagulation and suggest use of either a DOAC or low molecular weight heparin/vitamin K antagonist. We recommend anticoagulation for patients with cirrhosis and symptomatic PVT. We suggest anticoagulation for those with asymptomatic, progressing PVT and recommend continuing extended anticoagulation for liver transplant candidates with PVT.
Inclusion Criteria
Male, Female, Adult, Older adult
Health Care Settings
Ambulatory, Hospital, Outpatient
Intended Users
Nurse, nurse practitioner, physician, physician assistant
Scope
Treatment, Management, Prevention
Diseases/Conditions (MeSH)
D001281 - Atrial Fibrillation, D000925 - Anticoagulants, D008103 - Liver Cirrhosis, D011169 - Portal Vein
Keywords
atrial fibrillation, anticoagulation, cirrhosis, Stroke Prevention, VTE, Venous Thromboembolism, Portal Vein Thrombosis
Source Citation
Carlin S, Cuker A, Gatt A, Gendron N, Hernandez-Gea V, Meijer K, Siegal DM, Stanworth S, Lisman T, Roberts LN, Anticoagulation for Stroke Prevention in Atrial Fibrillation and Treatment of Venous Thromboembolism and Portal Vein Thrombosis in Cirrhosis: Guidance from the SSC of the ISTH, Journal of Thrombosis and Haemostasis (2024), doi: https://doi.org/10.1016/ j.jtha.2024.05.023.